Brusttumoren-Reference-Cited by-同舟云学术

Brusttumoren

Published:2024 Issue: Volume: Page:169-202
ISSN:
Container-title:PET/CT-Atlas
language:de
Short-container-title:

Author:

Mohnike Wolfgang,Mohnike Konrad,Kleine-Tebbe Anke,Lampe Matthias

Publisher

Springer Berlin Heidelberg

Link

https://link.springer.com/content/pdf/10.1007/978-3-662-67192-4_8

Reference49 articles.

1. International Agency for Research on Cancer, World Health Organization (2020) All cancers fact sheet. Global Cancer Observatory. https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. Zugegriffen: 21. Juni 2021

2. Mo JA (2021) Safety and effectiveness of F-18 Fluoroestradiol positron emission Tomography/computed Tomography: a systematic review and meta-analysis. J Korean Med Sci 36(42):e271. https://doi.org/10.3346/jkms.2021.36.e271

3. Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R (2021) Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review. Int J Mol Sci 22(20):11192. https://doi.org/10.3390/ijms222011192

4. Sadaghiani MS, Rowe SP, Sheikhbahaei S (2021) Applications of artificial intelligence in oncologic 18F-FDG PET/CT imaging: a systematic review. Ann Transl Med 9(9):823. https://doi.org/10.21037/atm-20-6162

5. Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S, Calvo L, Ribelles N, Martinez N, Albacar C, Prat A, Dalenc F, Kerrou K, Colleoni M, Afonso N, Di Cosimo S, Sampayo-Cordero M, Malfettone A, Cortés J, Llombart-Cussac A, PHERGain steering committee and trial investigators (2021) Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol 22(6):122–124. https://doi.org/10.1016/S1470-2045